Wen D, Li W, Song X, Hu M, Liao Y, Xu D
Cell Death Dis. 2025; 16(1):124.
PMID: 39987248
PMC: 11847022.
DOI: 10.1038/s41419-025-07453-y.
Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L
Front Immunol. 2025; 16:1518664.
PMID: 39949765
PMC: 11821961.
DOI: 10.3389/fimmu.2025.1518664.
Shi Y, McKenery A, Dolan M, Mastri M, Hill J, Dommer A
EMBO Rep. 2024; 26(2):521-559.
PMID: 39663510
PMC: 11772817.
DOI: 10.1038/s44319-024-00333-0.
Cao Y, Yi Y, Han C, Shi B
Front Immunol. 2024; 15:1476030.
PMID: 39493763
PMC: 11530992.
DOI: 10.3389/fimmu.2024.1476030.
Pan C, Wang Z, Wang Q, Wang H, Deng X, Chen L
Transl Lung Cancer Res. 2024; 13(9):2116-2138.
PMID: 39430326
PMC: 11484716.
DOI: 10.21037/tlcr-24-50.
Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response.
Tan L, Yin T, Xiang H, Wang L, Mudgal P, Chen J
Nat Commun. 2024; 15(1):8569.
PMID: 39362877
PMC: 11450162.
DOI: 10.1038/s41467-024-52902-5.
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.
Buyukbayram M, Hannarici Z, Duzkopru Y, Turhan A, Caglar A, Coban Esdur P
Breast Cancer (Dove Med Press). 2024; 16:329-339.
PMID: 38974895
PMC: 11227876.
DOI: 10.2147/BCTT.S464161.
Epigenomic analyses identify FOXM1 as a key regulator of anti-tumor immune response in esophageal adenocarcinoma.
Ziman B, Yang Q, Zheng Y, Sheth M, Nam C, Zhao H
Cell Death Dis. 2024; 15(2):152.
PMID: 38373993
PMC: 10876663.
DOI: 10.1038/s41419-024-06488-x.
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.
Malik P, Rani R, Solanki R, Patel V, Mukherjee T
Explor Target Antitumor Ther. 2023; 4(5):850-895.
PMID: 37970206
PMC: 10645466.
DOI: 10.37349/etat.2023.00171.
Nuclear factor kappa B expression in non-small cell lung cancer.
Zhang L, Ludden C, Cullen A, Tew K, de Barros A, Townsend D
Biomed Pharmacother. 2023; 167:115459.
PMID: 37716117
PMC: 10591792.
DOI: 10.1016/j.biopha.2023.115459.
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.
Shen C, Li M, Duan Y, Jiang X, Hou X, Xue F
Front Immunol. 2023; 14:1170207.
PMID: 37304265
PMC: 10250615.
DOI: 10.3389/fimmu.2023.1170207.
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.
Zheng H, Yu X, Ibrahim M, Foresman D, Xie M, Johnson J
Cancer Immunol Res. 2023; 11(4):466-485.
PMID: 36757308
PMC: 10165690.
DOI: 10.1158/2326-6066.CIR-22-0927.
Inflammatory cytokine-enriched microenvironment plays key roles in the development of breast cancers.
Takeuchi Y, Gotoh N
Cancer Sci. 2023; 114(5):1792-1799.
PMID: 36704829
PMC: 10154879.
DOI: 10.1111/cas.15734.
NEMO- and RelA-dependent NF-κB signaling promotes small cell lung cancer.
Koerner L, Schmiel M, Yang T, Peifer M, Buettner R, Pasparakis M
Cell Death Differ. 2023; 30(4):938-951.
PMID: 36653597
PMC: 10070460.
DOI: 10.1038/s41418-023-01112-5.
Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives.
Zulfiqar B, Farooq A, Kanwal S, Asghar K
Front Pharmacol. 2022; 13:1035171.
PMID: 36518665
PMC: 9742438.
DOI: 10.3389/fphar.2022.1035171.
In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer.
Liu L, Lei Y, Chen W, Zhou Q, Zheng Z, Zeng G
Cell Biosci. 2022; 12(1):193.
PMID: 36457047
PMC: 9717477.
DOI: 10.1186/s13578-022-00933-0.
Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation.
Yu G, Chen Y, Hu Y, Zhou Y, Ding X, Zhou X
Front Cell Dev Biol. 2022; 10:1010639.
PMID: 36438567
PMC: 9692235.
DOI: 10.3389/fcell.2022.1010639.
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
Sullivan K, Jiang X, Guha P, Lausted C, Carter J, Hsu C
Gut. 2022; 72(2):325-337.
PMID: 35705369
PMC: 9872249.
DOI: 10.1136/gutjnl-2021-325808.
Non-Canonical NF-κB Signaling Stratifies LGG into Subtypes with Distinct Molecular and Cellular Characteristic and Survival Expectancy.
Lin M, Huang T, Wang X, Li X, Ma J, Su L
Int J Gen Med. 2022; 15:3677-3686.
PMID: 35411180
PMC: 8994666.
DOI: 10.2147/IJGM.S347654.
Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
Koyama Y, Kawai S, Uenaka N, Okazaki M, Asaoka M, Teraoka S
Cancer Diagn Progn. 2022; 1(5):435-441.
PMID: 35403160
PMC: 8962857.
DOI: 10.21873/cdp.10058.